Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease

1

Dapagliflozin significantly improved cardiac function and myocardial performance in patients with T2DM and CHD compared to conventional treatment.
2

The dapagliflozin group showed greater enhancements in left ventricular ejection fraction and exercise tolerance after 4 weeks of treatment.
3

Dapagliflozin was associated with improved cardiac electrophysiological activity, including longer QT and Tp-Te intervals and reduced ST depression.
4

Adverse cardiovascular event rates were similar between the dapagliflozin and conventional treatment groups, indicating safety.
5

This study highlights the potential of dapagliflozin as an adjunctive therapy for improving cardiac outcomes in high-risk T2DM patients with CHD.

Frontiers In Cardiovascular Medicine

1